Corrigendum to “Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials” [Eur. Urol. Open Sci. 83 (2026) 133–141]

相似書籍

• Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
  由: Elisabeth E. Fransen van de Putte, et al.
  出版: (2023-09-01)
• Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
  由: Tomoki Taniguchi, et al.
  出版: (2024-12-01)
• Corrigendum to “Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials” [Eur. Urol. Open Sci. 83 (2026) 133–141]
  由: Leo Bickley, et al.
  出版: (2026-07-01)
• A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma
  由: Patrik Palacka, et al.
  出版: (2026-03-01)
• Results of combined nivolumab and ipilimumab therapy in patients with cancer
  由: M. A. Lyadova, et al.
  出版: (2021-12-01)